KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite sublingual allergy immunotherapy (SLIT) tablet. The BLA for Merck's investigational house dust mite SLIT-tablet is supported by a comprehensive clinical program involving more than 4,000 patients, including two Phase III in-field trials that ev-Pharmacodia